OBJECTIVE: To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria for Systemic Lupus Erythematosus (SLE) in terms of earlier SLE classification in comparison to the ACR or the Systemic Lupus International Collaborating Clinics (SLICC) criteria. MATERIALS AND METHODS: Patients from a multiethnic, multicenter cohort, the LUMINA cohort, where SLE was defined using the 1982/1997 ACR criteria were included. Demographic, clinical, and immunologic criteria were compared among the 2019 EULAR/ACR and the 1982/1997 ACR and the 2012 SLICC timing categories. RESULTS: The 2019 EULAR/ACR criteria allowed an earlier SLE classification in 13.3% (mean 0.66 years) and 15.3% (mean 0.63 years) than the 1982/1997 ACR and the 2012 SLICC criteria, respectively. Patients accruing the 2019 EULAR/ACR later than the 1982/1997 ACR criteria had a lower disease activity, were less likely to have positivity to anti-dsDNA and anti-Sm as well as lupus nephritis type II or V; they were more likely to have mucocutaneous manifestations, serositis, leukopenia and antiphospholipid antibodies positivity. These differences were less pronounced when compared to the 2012 SLICC criteria CONCLUSIONS: The 2019 EULAR/ACR criteria classified SLE patients earlier than with the two other criteria sets in real-life clinical practice scenarios in a relatively small proportion of the patients. However, these criteria could classify earlier a subset of patients with a more severe disease.